| Literature DB >> 33515712 |
Jianhong Kang1, Ting Chen2, Honghe Luo3, Yifeng Luo4, Guipeng Du5, Mia Jiming-Yang6.
Abstract
To develop a modified predictive model for severe COVID-19 in people infected with Sars-Cov-2. We developed the predictive model for severe patients of COVID-19 based on the clinical date from the Tumor Center of Union Hospital affiliated with Tongji Medical College, China. A total of 151 cases from Jan. 26 to Mar. 20, 2020, were included. Then we followed 5 steps to predict and evaluate the model: data preprocessing, data splitting, feature selection, model building, prevention of overfitting, and Evaluation, and combined with artificial neural network algorithms. We processed the results in the 5 steps. In feature selection, ALB showed a strong negative correlation (r = 0.771, P < 0.001) whereas GLB (r = 0.661, P < 0.001) and BUN (r = 0.714, P < 0.001) showed a strong positive correlation with severity of COVID-19. TensorFlow was subsequently applied to develop a neural network model. The model achieved good prediction performance, with an area under the curve value of 0.953(0.889-0.982). Our results showed its outstanding performance in prediction. GLB and BUN may be two risk factors for severe COVID-19. Our findings could be of great benefit in the future treatment of patients with COVID-19 and will help to improve the quality of care in the long term. This model has great significance to rationalize early clinical interventions and improve the cure rate.Entities:
Keywords: Machine learning; Predictive model; Severe COVID-19
Mesh:
Substances:
Year: 2021 PMID: 33515712 PMCID: PMC7840410 DOI: 10.1016/j.meegid.2021.104737
Source DB: PubMed Journal: Infect Genet Evol ISSN: 1567-1348 Impact factor: 4.393
Data collected.
| Data type | Parameter |
|---|---|
| Quantitative | Age, RBCs, Hb, WBCs, TP, ALB, GLB, CREA, BUN, mycoplasma IgM, mycoplasma IgG, chlamydial IgM |
| Categorical | Patient condition (mild cases, moderate cases, severe cases, and critical cases), sex, diabetes, diabetes with complications, acquired immune deficiency syndrome, cancer, history of lung disease, solitary patchy foci, multiple patchy foci, solitary ground-glass opacity, multiple ground-glass opacity, diffuse interstitial change, solitary interstitial change, solitary pulmonary consolidation, multiple pulmonary consolidations, solitary infiltrate, multiple infiltrates, chronic kidney diseases (>3 months) |
| Ordinal | Hypertension classification |
ALB, albumin; BUN, blood urea nitrogen; GLB, globulin; CREA, creatinine; Hb, hemoglobin; IgG, immunoglobulin G; IgM, immunoglobulin M; RBCs, red blood cells; TP, total protein; WBCs, white blood cells.
Measured according to the 2017 edition of American College of Cardiology/American Heart Association guidelines for hypertension.
Criteria for assessing COVID-19 severity.
| Severity | Criteria |
|---|---|
| Mild | Minimal symptoms without pulmonary involvement in chest imaging studies |
| Moderate | Fever and/or respiratory symptoms; multiple limited patchy shadows and interstitial changes in chest imaging |
| Severe | Dyspnea with a respiratory rate > 30 breaths per minute; resting oxygen saturation < 95% or arterial blood oxygen partial pressure/oxygen concentration ≤ 300 mmHg (1 mmHg = 0.133 kPa); multilobular disease or lesion progression >50% within 48 h; SOFA ≥2 points; pneumothorax and/or other |
| Critically ill | Respiratory failure requiring mechanical ventilation; septic shock; additional organ failure |
SOFA, sequential organ failure assessment.
Fig. 1The impact of learning rate on the model performance.
Fig. 2Data preprocessing.
Correlation analysis.
| Features | Correlation coefficient | P-value | Significance level | |
|---|---|---|---|---|
| Kendall correlation coefficient | Sex | −0.031 | 0.754 | |
| Hypertension classification | −0.011 | 0.722 | ||
| Chronic kidney diseases | 0.123 | 0.200 | ||
| Cardiac functional grading | 0.107 | 0.052 | ||
| Diabetes | −0.124 | 0.875 | ||
| AIDS | – | – | ||
| Cancer | 0.091 | 0.072 | ||
| History of lung disease | 0.137 | 0.011 | <0.05 | |
| Solitary patchy foci | −0.058 | 0.141 | ||
| Multiple patchy foci | −0.032 | 0.717 | ||
| Solitary ground-glass opacity | 0.076 | 0.954 | ||
| Multiple ground-glass opacity | 0.033 | 0.231 | ||
| Solitary interstitial change | 0.064 | 0.132 | ||
| Diffuse interstitial change | 0.026 | 0.223 | ||
| Solitary pulmonary consolidation | −0.040 | 0.852 | ||
| Multiple pulmonary consolidations | 0.160 | 0.162 | ||
| Solitary infiltrate | −0.136 | 0.149 | ||
| Multiple infiltrates | −0.136 | 0.472 | ||
| Pearson correlation coefficient | Age | 0.266 | 0.007 | <0.05 |
| WBC | 0.145 | 0.153 | ||
| RBC | −0.111 | 0.272 | ||
| Hb | −0.231 | 0.021 | <0.05 | |
| TP | −0.075 | 0.459 | ||
| ALB | −0.771 | 0.000 | <0.05 | |
| GLB | 0.661 | 0.000 | <0.05 | |
| CREA | 0.069 | 0.497 | ||
| BUN | 0.714 | 0.000 | <0.05 | |
| Mycoplasma immunoglobulin M | −0.069 | 0.496 | ||
| Mycoplasma immunoglobulin G | −0.138 | 0.171 | ||
| Chlamydial immunoglobulin M | −0.107 | 0.291 | ||
| Chlamydial immunoglobulin G | −0.137 | 0.177 |
AIDS, acquired immunodeficiency syndrome’ ALB, albumin; BUN, blood urea nitrogen; GLB, globulin; CREA, creatinine; Hb, hemoglobin; RBCs, red blood cells; TP, total protein; WBCs, white blood cells.
Fig. 3Data distribution.
Fig. 4Changes in residual error.
Fig. 5The final model.
Fig. 6ROC curve of our model.
Fig. 7Imaging manifestations of severe COVID-19 (a) before treatment, (b) during treatment, and (c) after treatment.